CN112262141A - 可用作线粒体解偶联剂的咪唑吡啶 - Google Patents

可用作线粒体解偶联剂的咪唑吡啶 Download PDF

Info

Publication number
CN112262141A
CN112262141A CN201980038722.7A CN201980038722A CN112262141A CN 112262141 A CN112262141 A CN 112262141A CN 201980038722 A CN201980038722 A CN 201980038722A CN 112262141 A CN112262141 A CN 112262141A
Authority
CN
China
Prior art keywords
trifluoromethyl
alkyl
phenyl
amine
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980038722.7A
Other languages
English (en)
Chinese (zh)
Inventor
韦伯斯特·L·桑托斯
戴昱旻
约瑟·A·圣地亚哥-里韦拉
雅各布·H·默里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Tech Intellectual Properties Inc
Original Assignee
Virginia Tech Intellectual Properties Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intellectual Properties Inc filed Critical Virginia Tech Intellectual Properties Inc
Publication of CN112262141A publication Critical patent/CN112262141A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
CN201980038722.7A 2018-04-20 2019-04-22 可用作线粒体解偶联剂的咪唑吡啶 Pending CN112262141A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862660880P 2018-04-20 2018-04-20
US62/660,880 2018-04-20
PCT/US2019/028555 WO2019204816A1 (en) 2018-04-20 2019-04-22 Imidazopyridines useful as mitochondrial uncouplers

Publications (1)

Publication Number Publication Date
CN112262141A true CN112262141A (zh) 2021-01-22

Family

ID=67139787

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980038722.7A Pending CN112262141A (zh) 2018-04-20 2019-04-22 可用作线粒体解偶联剂的咪唑吡啶
CN201980038852.0A Pending CN112261941A (zh) 2018-04-20 2019-04-22 可用作线粒体解偶联剂的氨基吡嗪及相关化合物
CN201980038732.0A Pending CN112262146A (zh) 2018-04-20 2019-04-22 可用作线粒体解偶联剂的噁二唑并吡嗪和噁二唑并吡啶

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980038852.0A Pending CN112261941A (zh) 2018-04-20 2019-04-22 可用作线粒体解偶联剂的氨基吡嗪及相关化合物
CN201980038732.0A Pending CN112262146A (zh) 2018-04-20 2019-04-22 可用作线粒体解偶联剂的噁二唑并吡嗪和噁二唑并吡啶

Country Status (12)

Country Link
US (3) US11708376B2 (https=)
EP (3) EP3781165A4 (https=)
JP (3) JP2021523933A (https=)
KR (3) KR20210003831A (https=)
CN (3) CN112262141A (https=)
AU (2) AU2019256719A1 (https=)
BR (2) BR112020021466A2 (https=)
CA (2) CA3097752A1 (https=)
IL (2) IL278070A (https=)
MX (2) MX2020011049A (https=)
WO (3) WO2019204819A1 (https=)
ZA (2) ZA202006295B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708376B2 (en) * 2018-04-20 2023-07-25 Virginia Tech Intellectual Properties, Inc. Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers
WO2020191503A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4482494A4 (en) * 2022-02-21 2026-02-25 Univ Colorado Regents RE-SENSITIZATION OF MULTI-DRUG-RESISTANT GRAM-NEGATIVE (MDR) BACTERIA TO COLISTIN USING IONOPHORES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192388A1 (en) * 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2017151063A1 (en) * 2016-03-03 2017-09-08 Agency For Science, Technology And Research Use of furazano[3,4-b]pyrazine derivatives for chemotherapy
WO2018217757A1 (en) * 2017-05-22 2018-11-29 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2501680A1 (fr) 1981-03-12 1982-09-17 Elf Aquitaine Synthese de tetra mercaptides stanniques
US4472840A (en) 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US5606019A (en) 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
JP2668259B2 (ja) * 1988-02-18 1997-10-27 塩野義製薬株式会社 複素環化合物および抗潰瘍剤
GB2215209B (en) 1988-03-14 1992-08-26 Osmed Inc Method and apparatus for biodegradable, osteogenic, bone graft substitute device
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH0327172A (ja) 1989-06-19 1991-02-05 Nissan Chem Ind Ltd 布の漂白方法
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
JPH0741461A (ja) * 1993-05-27 1995-02-10 Eisai Co Ltd スルホン酸エステル誘導体
EP1424072A1 (en) * 1999-03-03 2004-06-02 Samjin Pharmaceutical Co., Ltd. N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors
PL365238A1 (en) * 2000-02-16 2004-12-27 Neurogen Corporation Substituted arylpyrazines
WO2002020463A2 (en) * 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2005044270A1 (en) 2003-11-04 2005-05-19 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
EP1529531A1 (en) * 2003-11-04 2005-05-11 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
EP1799689A1 (en) 2004-10-14 2007-06-27 Compass Pharmaceuticals LLC Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
CA2626220A1 (en) * 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
EP2017277A1 (en) * 2007-06-29 2009-01-21 4Sc Ag Thiophene-imidazopyridines
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
BRPI1013904A2 (pt) * 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
JP6075621B2 (ja) * 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
JP6073343B2 (ja) * 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
KR101481952B1 (ko) * 2012-04-13 2015-01-22 한국과학기술연구원 신경보호제로서의 유레아 유도체
TW201441203A (zh) 2012-11-05 2014-11-01 Medeia Therapeutics Ltd Ｎ－取代４－胺苯酚及對應醌亞胺
CA2917262A1 (en) * 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
KR101428622B1 (ko) * 2014-01-07 2014-08-13 국방과학연구소 옥사디아졸로 피라진기를 포함하는 화합물 또는 염을 포함하는 리튬 이차 전지용 전극 및 이를 포함하는 리튬 이차 전지
CA2965781A1 (en) * 2014-10-28 2016-05-06 Shionogi & Co., Ltd. Heterocyclic derivative having ampk activating effect
CA2968299A1 (en) * 2014-11-18 2016-05-26 Rutgers, The State University Of New Jersey Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
US11708376B2 (en) * 2018-04-20 2023-07-25 Virginia Tech Intellectual Properties, Inc. Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192388A1 (en) * 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
US20170240563A1 (en) * 2012-06-20 2017-08-24 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2017151063A1 (en) * 2016-03-03 2017-09-08 Agency For Science, Technology And Research Use of furazano[3,4-b]pyrazine derivatives for chemotherapy
WO2018217757A1 (en) * 2017-05-22 2018-11-29 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers

Also Published As

Publication number Publication date
MX2020011050A (es) 2021-03-09
CN112262146A (zh) 2021-01-22
WO2019204816A1 (en) 2019-10-24
KR20210011928A (ko) 2021-02-02
CN112261941A (zh) 2021-01-22
CA3097751A1 (en) 2019-10-24
KR102900692B1 (ko) 2025-12-15
AU2019256722A1 (en) 2020-11-05
MX2020011049A (es) 2021-01-08
ZA202006296B (en) 2023-03-29
IL278070A (en) 2020-11-30
IL278069A (en) 2020-11-30
EP3781572A1 (en) 2021-02-24
WO2019204813A1 (en) 2019-10-24
EP3781165A4 (en) 2022-02-23
US20210238181A1 (en) 2021-08-05
KR102913366B1 (ko) 2026-01-14
JP2021523934A (ja) 2021-09-09
US20210253594A1 (en) 2021-08-19
US11708376B2 (en) 2023-07-25
JP2021523933A (ja) 2021-09-09
ZA202006295B (en) 2023-03-29
EP3781567A1 (en) 2021-02-24
EP3781567B1 (en) 2022-08-24
KR20210003831A (ko) 2021-01-12
WO2019204819A1 (en) 2019-10-24
KR20210009321A (ko) 2021-01-26
US20210253538A1 (en) 2021-08-19
BR112020021469A2 (pt) 2021-01-19
AU2019256719A1 (en) 2020-11-05
BR112020021466A2 (pt) 2021-01-19
EP3781165A1 (en) 2021-02-24
JP2021522327A (ja) 2021-08-30
CA3097752A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
US11254653B2 (en) NLRP3 inflammasome inhibitors
CN112262141A (zh) 可用作线粒体解偶联剂的咪唑吡啶
TWI674257B (zh) 作為ｔｒｐｍ８拮抗劑之氮雜螺衍生物
CA2903293C (en) Heterocyclic compounds and uses thereof
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
ES2526981T3 (es) N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
KR102090944B1 (ko) Ttx-s 차단제로서의 피롤로피리디논 유도체
EP4259617B1 (en) Substituted pyrazolo piperidine carboxylic acids
EP4259618B1 (en) Substituted pyrazolyl piperidine carboxylic acids
AU2023417544A1 (en) Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof
TW201202213A (en) Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics
HK40046949B (en) Imidazopyridines useful as mitochondrial uncouplers
HK40046949A (en) Imidazopyridines useful as mitochondrial uncouplers
EP4351574B1 (en) Inhibitors of ttbk1
CN113801135B (zh) 噻吩并吡唑类化合物，包含其的药物组合物及其用途
WO2020244607A1 (zh) P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210122

WD01 Invention patent application deemed withdrawn after publication